Free Trial

Allianz SE Has $772,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lantheus logo with Medical background

Key Points

  • Allianz SE increased its holdings in Lantheus Holdings, Inc. by 103.4% in Q1, now owning 7,906 shares valued at $772,000.
  • Institutional investors own 99.06% of Lantheus stock, with significant purchases from hedge funds including a new position from Norges Bank worth about $26 million.
  • Analysts have mixed ratings on Lantheus, with a consensus rating of "Moderate Buy" and a price target averaging $131.20.
  • Interested in Lantheus? Here are five stocks we like better.

Allianz SE grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 103.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,906 shares of the medical equipment provider's stock after acquiring an additional 4,020 shares during the period. Allianz SE's holdings in Lantheus were worth $772,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LNTH. Norges Bank bought a new position in Lantheus during the fourth quarter valued at about $26,189,000. Pictet Asset Management Holding SA lifted its holdings in Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock worth $921,000 after purchasing an additional 1,113 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Lantheus in the 4th quarter worth approximately $20,022,000. Massachusetts Financial Services Co. MA grew its stake in Lantheus by 37.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 323,900 shares of the medical equipment provider's stock valued at $28,976,000 after buying an additional 87,412 shares during the last quarter. Finally, Foundry Partners LLC increased its stake in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. William Blair reissued a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, Truist Financial cut their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.20.

View Our Latest Analysis on LNTH

Lantheus Trading Down 0.9%

LNTH stock opened at $70.57 on Monday. Lantheus Holdings, Inc. has a 1-year low of $69.12 and a 1-year high of $118.21. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The business's 50 day moving average is $77.65 and its 200-day moving average is $87.91. The firm has a market cap of $4.88 billion, a P/E ratio of 20.05 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business's revenue was up .8% on a year-over-year basis. During the same quarter last year, the company earned $1.69 earnings per share. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lantheus Right Now?

Before you consider Lantheus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.

While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines